Latest news

• Regeneron scores positive data in phase 3 cholesterol trial

  Despite patients already taking lipid-lowering treatments, such as statins and PCSK9 inhibitors, their levels of cholesterol remained dangerously high prior to enrolment in the study. ... Regeneron and partner Sanofi have another approved

• England opens new NHS ‘front door’ to health innovators

  Most significantly for pharma, only two of these areas related to medicines: the PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia, Amgen’s Repatha and Sanofi’s Praluent, as

• Sanofi gets cardio outcomes claim for Praluent in EU

  The two PCSK9 inhibitors are locked in a battle for the severe, high-risk end of the cholesterol market – mainly patients who are unable to control low-density lipoprotein (LDL) cholesterol ... Complicating the picture is a global intellectual property

• MS and cholesterol drugs picked for new UK rapid uptake push

  baby. PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia  - Cost-effective drugs that significantly lower cholesterol.

• CETP inhibitor class finally dies as Merck abandons anacetrapib

  The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have